Phase 2 Oesophageal Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with esophageal squamous cell carcinoma (a specific type of oesophageal cancer) confirmed by a tissue test
• People aged between 18 and 75 years old
• People whose cancer is at clinical stage II, III, or IVa
• People who have not previously had any cancer treatment, such as immunotherapy or chemoradiotherapy
• People who are generally well enough to carry out light daily activities (rated 0 or 1 on a standard health performance scale)
• People whose blood counts, liver function, kidney function, blood sugar, and lung function meet specific medical thresholds set by the trial (confirm with trial site for exact values)
• Women of childbearing age who are not surgically sterilised must have a negative pregnancy test within 72 hours before joining, must not be breastfeeding, and must agree to use an approved form of contraception during the trial and for 3 months after treatment ends
• Male participants whose partners could become pregnant must agree to use effective contraception during the trial and for 3 months after the last dose
• People who are willing and able to sign a consent form agreeing to take part

Who may not be able to join:

• People whose tissue test shows a mixed or combined type of squamous cell carcinoma, such as squamous adenocarcinoma, carcinosarcoma, or sarcomatoid carcinoma
• People who have previously had most of their stomach surgically removed (subtotal gastrectomy)
• People who have a second, separate cancer at the same time
• People whose pre-treatment scans show the cancer has spread to distant parts of the body
• People who have previously received chemoradiotherapy
• People showing signs that the oesophagus may have a hole or tear (perforation)
• Women who are pregnant
• People who have an active autoimmune disease, or a history of one, such as autoimmune hepatitis, interstitial pneumonia, uveitis, bowel inflammation, thyroid disease, vasculitis, or similar conditions
• People with active infectious diseases including active tuberculosis, active hepatitis, or known HIV infection
• People with a known bleeding disorder or another serious uncontrolled condition that cannot be treated with surgery
• People whose physical examination or test results suggest that joining the trial could interfere with results or put them at greater risk of complications, as judged by the research team
• People with a history of interstitial lung disease, drug-induced lung disease, or radiation-related lung inflammation that required steroid treatment, or who have idiopathic pulmonary fibrosis visible on a baseline CT scan, or who have large uncontrolled fluid collections around the lungs or heart
• People with unstable or poorly controlled health conditions such as active infections, moderate-to-severe chronic obstructive pulmonary disease (COPD), uncontrolled high blood pressure, unstable chest pain, heart failure, a heart attack within the past 6 months, severe mental health conditions requiring medication, or serious liver, kidney, or neurological conditions such as Alzheimer's disease
• People with digestive problems such as malabsorption syndrome or active stomach or bowel ulcers
• People who have previously been treated with anti-PD-1 or anti-PD-L1 medications (a type of immunotherapy)
• People who have received another experimental drug within 4 weeks before joining this trial
• People currently enrolled in another interventional clinical trial (observational studies may be acceptable — confirm with trial site)
• People who have needed regular steroid treatment at higher than a low specified dose, or other immune-suppressing medications, within 2 weeks before joining (some exceptions may apply — confirm with trial site)
• People who have received an anti-cancer vaccine, or any live vaccine, within 4 weeks before joining
• People who have had major surgery or a serious injury within 4 weeks before joining
• People with a congenital or acquired immune deficiency, or a history of organ transplantation
• People with known allergies to monoclonal antibodies or any of the trial medications, including albumin-bound paclitaxel, 5-fluorouracil, cisplatin, or other platinum-based drugs

Important: Always verify eligibility with the trial site directly before applying.